MTOR and cancer: This, in turn, can enable combating widespread strategies used by cancer cells to resist the action of drugs, such as MET amplification or PI3K/AKT activation after targeted EGFR inhibition, PI3K/AKT compensation after mTOR inhibition, or MAPK/STAT3 cross-talk [14].